These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 10248995)
1. FDA NPRM would standardize blood labeling to permit inventory automation. McNeal BM Health Law Vigil; 1980 Dec; 3(24):6-7. PubMed ID: 10248995 [No Abstract] [Full Text] [Related]
2. Revisions to labeling requirements for blood and blood components, including source plasma. Final rule. Food and Drug Administration, HHS Fed Regist; 2012 Jan; 77(1):7-18. PubMed ID: 22242229 [TBL] [Abstract][Full Text] [Related]
3. Revisions to the requirements applicable to blood, blood components and source plasma; confirmation of effective date and technical amendment. Direct final rule; confirmation of effective date and technical amendment. Food and Drug Administration, HHS Fed Regist; 2008 Feb; 73(27):7463-4. PubMed ID: 18389917 [TBL] [Abstract][Full Text] [Related]
4. Reaction mixed on value of new FDA regulations for dialyzer relabelling. Boudreau D Nephrol News Issues; 1995 Oct; 9(10):7-8. PubMed ID: 7494593 [No Abstract] [Full Text] [Related]
6. Patient safety or profit: what incentives are blood shield laws and FDA regulations creating for the tissue banking industry? Williams JL Indiana Health Law Rev; 2005; 2(1):295-328. PubMed ID: 17111505 [No Abstract] [Full Text] [Related]
7. Physical restraints: an FDA update. Weick MD Am J Nurs; 1992 Nov; 92(11):74-80. PubMed ID: 1485634 [No Abstract] [Full Text] [Related]
8. Cross-referencing of ISO-9000 and regulatory quality systems at blood centers. Healy-Collier K Top Health Inf Manage; 1998 May; 18(4):32-8. PubMed ID: 10179274 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C screening and notification: hospitals under new FDA regulations. Thomas M; Favata-Bosh DM QRC Advis; 1999 Jan; 15(3):1-5. PubMed ID: 10345516 [No Abstract] [Full Text] [Related]
10. The FDA as an information source for family physicians. Rheinstein PH Am Fam Physician; 1991 Sep; 44(3):1037-41. PubMed ID: 1877417 [No Abstract] [Full Text] [Related]
11. Revisions to the requirements applicable to blood, blood components, and source plasma. Final rule. Food and Drug Administration, HHS Fed Regist; 2001 Aug; 66(151):40886-90. PubMed ID: 11732557 [TBL] [Abstract][Full Text] [Related]
12. Implementing the ISBT 128 labeling standard in a transfusion service. Tiehen A; Swanson S MLO Med Lab Obs; 1998 May; 30(5):18-9, 22-3, 26-7. PubMed ID: 10179684 [No Abstract] [Full Text] [Related]
13. Developing your ISBT 128 implementation plan. 12 things to consider in preparing for the new standard. Silva MA MLO Med Lab Obs; 2006 Sep; 38(9):40, 42-3. PubMed ID: 17024931 [No Abstract] [Full Text] [Related]
14. FDA could OK costly blood standards. An expert says that like chicken soup, removal of white cells from blood supply can't hurt. Hensley S Mod Healthc; 1999 Nov; 29(48):8. PubMed ID: 10662211 [No Abstract] [Full Text] [Related]
15. Product labeling: the FDA perspective. Barlow DA J Enterostomal Ther; 1986; 13(5):178-9. PubMed ID: 3639092 [No Abstract] [Full Text] [Related]
16. New Federal guidelines for hepatitis C virus lookback. Witthaus D MLO Med Lab Obs; 1998 Sep; 30(9):22-6. PubMed ID: 10186315 [TBL] [Abstract][Full Text] [Related]
17. New glutaraldehyde labeling controversial. Patterson P OR Manager; 1995 Sep; 11(9):26. PubMed ID: 10144942 [No Abstract] [Full Text] [Related]
18. Medical devices; hearing aids; technical data amendments. Direct final rule. Food and Drug Administration, HHS Fed Regist; 2008 Jun; 73(106):31358-60. PubMed ID: 18677822 [TBL] [Abstract][Full Text] [Related]